Sangamo’s ST-920 demonstrates evidence of clinical benefit
Phase 1/2 research shows that treatment could be very effective against Fabry disease
Read More
Tag: Fabry
NICE backs Amicus’ Galafold for Fabry disease
The National Institute for Health and Care Excellence is backing National Health Service use of Amicus Therapeutics’ Galafold for treating the rare genetic disorder Fabry disease.
Read More
- Tozorakimab shows significant benefit in two major COPD trials
- Daratumumab becomes first oncology injectable approved for patient administration
- Laigo Bio completes final close of €17m seed financing round
- Axplora announces expansion as newest part of $60m API investment programme
- DNA Script signs SYNTAX distribution agreements with Gencell, BMS and Biostream
